Organon News & Analysis
2 articles
Market Mood
Sun Pharmaceuticals (SUN) Acquires Organon & Co for $11.75 Billion
Sun Pharmaceuticals (SUN) announced an agreement to acquire Organon & Co for $11.75 billion, marking the largest overseas acquisition by an Indian company in nearly 20 years. This deal is part of a broader trend, with 162 Indian companies investing over $18 billion in outbound acquisitions in 2025, reflecting a 34% year-over-year increase. Notable acquisitions include Tata Motors' $4.4 billion purchase and IT firm Coforge's $2.35 billion acquisition. Analysts suggest that Indian firms are increasingly seeking overseas assets for strategic rather than merely symbolic reasons.
Read More
Sun Pharma (SUN) Acquires Organon for $11.75 Billion in Cash
Sun Pharmaceutical Industries (SUN) announced its acquisition of Organon & Co for $11.75 billion, valuing the U.S. firm at $14 per share including debt. This deal will position Sun Pharma among the top 25 global pharmaceutical companies, enhancing its revenue from $12.4 billion. The acquisition is expected to increase Sun Pharma's innovative medicine segment contribution to 27% from 20% in the financial year ending March 2025. Organon's portfolio supports Sun Pharma's strategy to grow its Innovative Medicines business, which includes dermatology and oncology products.
Read More